Vor bio doses first aml patient with vcar33 (allo) and provides corporate update

Cambridge, mass., jan. 17, 2024 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, announced today it has dosed the first patient in vbp301, its phase 1/2, multicenter, open-label, first-in-human study of vcar33allo. the company has extended its cash runway into the second half of 2025.
VOR Ratings Summary
VOR Quant Ranking